Denali Therapeutics Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, reporting a third-quarter net income of $70.1 million driven by a $194 million gain on the sale of a priority review voucher.

Key Highlights

  • Third-quarter net income: Denali reported net income of $70,126 thousand for the three months ended September 30, 2026, compared to a net loss of $126,902 thousand in the same period of 2025.
  • Priority review voucher sale: The company recorded a gain on the sale of a priority review voucher, net, of $194,000 thousand in the third quarter of 2026.
  • First product revenue: The company reported product revenue, net, of $17,778 thousand in Q3 2026 and $21,382 thousand for the nine months ended September 30, 2026, compared to zero in both comparable 2025 periods.
  • Nine-month net loss: For the nine months ended September 30, 2026, the company reported a net loss of $185,874 thousand, compared to a net loss of $383,991 thousand in the same period of 2025.
  • Revenue participation right liability: The balance sheet reflects a liability related to a revenue participation right agreement of $209,661 thousand as of September 30, 2026, which did not exist as of December 31, 2025.
  • Total assets: Total assets were $1,256,035 thousand as of September 30, 2026, up from $1,144,854 thousand as of December 31, 2025.
  • Shares outstanding: Common shares issued and outstanding were 160,257,940 as of September 30, 2026, with an additional 28,331,779 shares issuable upon exercise of pre-funded warrants as of October 28, 2026.

Denali Therapeutics Reports First Commercial Revenue and Voucher Gain in Q3 2026

According to the filing, Denali Therapeutics (NASDAQ:DNLI) recorded its first product revenue in 2026, generating $17,778 thousand in the third quarter and $21,382 thousand for the nine months ended September 30, 2026. The company disclosed cost of goods sold of $192 thousand for Q3 2026 and $285 thousand for the nine-month period, reflecting the early stage of commercial operations. Research and development expenses were $106,102 thousand for the three months ended September 30, 2026, compared to $101,950 thousand in Q3 2025, while selling, general and administrative expenses were $37,485 thousand versus $35,484 thousand in the prior-year quarter.

The company disclosed that a gain on the sale of a priority review voucher, net, of $194,000 thousand was recorded in the three months ended September 30, 2026, which was the primary driver of the quarterly net income of $70,126 thousand. For the nine-month period, total other income was $208,775 thousand, compared to $33,986 thousand in the comparable 2025 period, reflecting that voucher gain. The nine-month accumulated deficit increased to $2,237,398 thousand from $2,051,524 thousand at December 31, 2025, as the company reported a nine-month net loss of $185,874 thousand.

The balance sheet as of September 30, 2026, reflected several new line items compared to December 31, 2025, including accounts receivable, net, of $18,882 thousand; inventory of $26,275 thousand; and an intangible asset, net, of $34,500 thousand. A liability related to a revenue participation right agreement of $209,661 thousand also appeared for the first time. Total stockholders' equity decreased to $926,387 thousand from $1,013,761 thousand at December 31, 2025. The filing noted that as of October 28, 2026, there were 160,290,546 common shares outstanding, excluding 28,331,779 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.01 per share, subject to beneficial ownership limitations.

What Was Disclosed

Denali Therapeutics filed its quarterly report for the period ended September 30, 2026, disclosing first-ever product revenue, a $194 million priority review voucher gain that produced a quarterly net profit, a new revenue participation right liability, and an accumulated deficit of approximately $2.24 billion.